A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Immunovant, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 339,700 shares of IMVT stock, worth $8.97 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
339,700
Previous 18,300 1756.28%
Holding current value
$8.97 Million
Previous $771,000 1323.61%
% of portfolio
0.02%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$30.27 - $43.79 $9.73 Million - $14.1 Million
321,400 Added 1756.28%
339,700 $11 Million
Q4 2023

Feb 13, 2024

SELL
$31.31 - $44.19 $6.36 Million - $8.97 Million
-203,100 Reduced 91.73%
18,300 $771,000
Q3 2023

Nov 14, 2023

SELL
$18.55 - $39.96 $4.57 Million - $9.85 Million
-246,400 Reduced 52.67%
221,400 $8.5 Million
Q2 2023

Aug 11, 2023

SELL
$14.2 - $23.75 $345,230 - $577,410
-24,312 Reduced 4.94%
467,800 $8.87 Million
Q1 2023

May 12, 2023

BUY
$15.27 - $19.72 $2.26 Million - $2.92 Million
148,012 Added 43.01%
492,112 $7.63 Million
Q4 2022

Feb 13, 2023

SELL
$6.59 - $17.75 $55,356 - $149,100
-8,400 Reduced 2.38%
344,100 $6.11 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $78,207 - $126,763
19,900 Added 5.98%
352,500 $1.97 Million
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.65 $783,822 - $1.31 Million
231,900 Added 230.29%
332,600 $1.3 Million
Q1 2022

May 13, 2022

BUY
$5.06 - $8.77 $420,485 - $728,787
83,100 Added 472.16%
100,700 $555,000
Q4 2021

Feb 11, 2022

BUY
$7.33 - $9.32 $129,008 - $164,032
17,600 New
17,600 $150,000
Q1 2021

May 13, 2021

SELL
$13.08 - $49.6 $73,248 - $277,760
-5,600 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$36.36 - $52.71 $203,616 - $295,176
5,600 New
5,600 $259,000
Q3 2020

Nov 13, 2020

SELL
$22.61 - $38.9 $820,743 - $1.41 Million
-36,300 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$13.87 - $28.44 $503,481 - $1.03 Million
36,300 New
36,300 $884,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.41B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.